Navigation Links
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
Date:10/14/2008

s, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Hussey Copper , a leader in copper manufacturing ... Gilmour Academy Ice Arena,s conversion of more than 200 ... surface to help protect against bacteria.  MD-Cu 29 ... greater than 99.9% of MRSA, E-coli and other bacteria ... , Innovative Gilmour Academy prepares children ...
(Date:9/17/2014)... , 17 de septiembre de 2014 /PRNewswire/ ... principal proveedor mundial de soluciones logísticas avanzadas ... de la vida, anunció hoy la contratación ... global con sede en Rótterdam, Países Bajos, ... clientes Europa en rápido crecimiento. Según los ...
(Date:9/17/2014)... 17, 2014 The Pistoia Alliance, ... lowering the barriers to innovation in life sciences ... of Carmen Nitsche as Executive Director Business Development ... its global reach. , Carmen joins the Pistoia ... Corporate Development. At Accelrys, she managed various life ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
Breaking Biology Technology:Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Biocom Recognizes National Health IT Week 2
... SAN DIEGO, July 28, 2011 Gen-Probe Incorporated (NASDAQ: ... quarter of 2011, with total revenues of $135.9 million and ... "Gen-Probe posted record sales of APTIMA women,s health products in ... blood screening revenue to decline compared to strong sales a ...
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... the second quarter of 2011, the Company reported net income of ... of $5.2 million, or $0.09 loss per share, for the same ... the Company reported net income of $4.9 million, or $0.09 per ...
... ITMN ) today announced that it will release its ... A live conference call and webcast will be hosted by ... discuss business highlights and financial results for the second quarter ... the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ...
Cached Biology Technology:Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14Neurocrine Biosciences Reports Second Quarter 2011 Results 2Neurocrine Biosciences Reports Second Quarter 2011 Results 3Neurocrine Biosciences Reports Second Quarter 2011 Results 4Neurocrine Biosciences Reports Second Quarter 2011 Results 5Neurocrine Biosciences Reports Second Quarter 2011 Results 6Neurocrine Biosciences Reports Second Quarter 2011 Results 7InterMune to Release Second Quarter Financial Results on August 4 2
(Date:9/16/2014)... severe maternal morbidity amongst women in Australia is ... study published today (17 September) in BJOG: ... , Australians generally enjoy high standards of living; ... exist, in particular between indigenous and non indigenous ... the independent impact of socioeconomic position on severe ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... Biobanks are repositories for tissue samples, usually in ... from surgical procedures. These samples are collected and used ... linked to personal health information regarding the sample donor. ... researchers who want to use them face important questions ...
... The Life Sciences Discovery Fund (LSDF) today announced awards ... therapies and key resources for medical researchers and health-care ... the three programs. The programs will be led ... across the state. Dr. David Flum will work with ...
... MADISON, WI, JUNE 28, 2011 -- The ... provides information needed to sustainably manage agroforestry systems. ... increase yields and also reduce financial and environmental ... that allows for site-specific evaluation of nutrient-production imbalances ...
Cached Biology News:Public prefers limited informed consent process for biobanks 2Public prefers limited informed consent process for biobanks 3Life Sciences Discovery Fund helps launch 3 programs to advance health research and development 2Analyzing agroforestry management 2
... MKK6 (phospho S207) ( Abpromise ... Antigen: Synthetic phosphopeptide derived ... site of Serine 207 (V-D-S P ... ID: 5608 ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: